Medroxyprogesterone acetate in the treatment of pelvic pain due to venous congestion.
Ovarian function was suppressed with 30 mg of medroxyprogesterone acetate, daily for 6 months, in 22 women with lower abdominal pain due to pelvic congestion. There was reduction in pelvic congestion demonstrated by venography in 17 of the 22 women, and in 16 this was associated with induction of amenorrhoea which suggests that effective ovarian suppression is an important component of successful treatment. In the 17 women who showed a reduction in venogram score, the median change in pain score was 75% compared with only 29% in the five women with no change in venogram score (P less than 0.01). This significant association between reduction in pelvic congestion and pain indicates that pelvic congestion is likely to be the cause of pain in these women and that treatment with medroxyprogesterone acetate could be of value.
Reginald
P W
PW
St Mary's Hospital Medical School, London, Department of Obstetrics and Gynaecology.
Adams
J
J
Franks
S
S
Wadsworth
J
J
Beard
R W
RW
D000328:Adult; D004108:Dilatation, Pathologic; D004717:Endometrium / Q000473:pathology; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D010053:Ovary / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement; D010388:Pelvis / Q000098:blood supply / Q000000981:diagnostic imaging; D010690:Phlebography; D014463:Ultrasonography; D014680:Veins / Q000473:pathology
D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone